A controversial hepatitis B vaccine study in Guinea-Bissau is approved to proceed, with reporting that the trial would withhold or delay the vaccine for some newborns. The approval is described as a component of a wider vaccine program associated with Robert F. Kennedy Jr, a longtime vaccine critic who, according to the coverage, holds a role at the US Department of Health and Human Services.
Across outlets, the dispute centers on the trial design and the impact on infant protection. The Guardian reports that the “recommended dose” will be withheld from thousands of newborns by Danish researchers participating in the study. Other coverage summarised on Medium characterizes the research as flawed or misleading, arguing that the trial promotes an approach inconsistent with established vaccine guidance.
While the basic facts reported are that the study has approval to move forward in Guinea-Bissau and involves Danish researchers, the outlets differ in how they interpret the scientific rationale and implications for public health.
